- Home
- GYRE
as 01-17-2025 4:00pm EST
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 128.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.26 - $26.37 | Next Earning Date: | 11-13-2024 |
| Revenue: | $105,033,000 | Revenue Growth: | -9.04% |
| Revenue Growth (this year): | 25.32% | Revenue Growth (next year): | 12.95% |
Stock Insider Trading Activity of Gyre Therapeutics Inc. (GYRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ma Songjiang | GYRE | President | Jan 14 '25 | Sell | $10.62 | 4,000 | $42,480.00 | 2,911,138 | |
| Ma Songjiang | GYRE | President | Jan 10 '25 | Sell | $10.06 | 1,113 | $11,156.74 | 2,911,138 | |
| Ma Songjiang | GYRE | President | Jan 6 '25 | Sell | $10.09 | 2,216 | $22,336.06 | 2,911,138 | |
| Ma Songjiang | GYRE | President | Jan 2 '25 | Sell | $11.78 | 4,833 | $57,414.11 | 2,911,138 | |
| Ma Songjiang | GYRE | President | Dec 30 '24 | Sell | $12.75 | 4,000 | $50,553.08 | 2,911,138 | |
| Ma Songjiang | GYRE | President | Dec 23 '24 | Sell | $12.20 | 4,000 | $48,399.20 | 2,911,138 | |
| Ma Songjiang | GYRE | President | Dec 17 '24 | Sell | $11.36 | 4,000 | $44,851.78 | 2,911,138 |
Latest Gyre Therapeutics Inc. News
GYRE Breaking Stock News: Dive into GYRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Simply Wall St.
2 months ago
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)
GlobeNewswire
2 months ago
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Simply Wall St.
3 months ago
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt
GlobeNewswire
4 months ago
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
GlobeNewswire
4 months ago
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
5 months ago
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Compare GYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GYRE Gyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.